Content Type: Article

  • Corporate Transparency Act Update: Beneficial Ownership Reporting Rule Now Effective and FinCEN Is Accepting Reports

    Corporate Transparency Act Update: Beneficial Ownership Reporting Rule Now Effective and FinCEN Is Accepting Reports

    ARTICLE / CLIENT ALERT

    Corporate Transparency Act Update: Beneficial Ownership Reporting Rule Now Effective and FinCEN Is Accepting Reports

    January 4, 2024

    Read time: 5 min

    Key takeaways
    Overview

    On Jan. 1, 2024, the US Department of Treasury’s Financial Crimes Enforcement Network (“FinCEN”) beneficial ownership reporting rule (“BOI Rule”)[1] pursuant to the Corporate Transparency Act (“CTA”)[2] became effective. The BOI Rule requires certain legal entities formed or foreign entities registered to do business in the United States (“Reporting Company”) to file a beneficial ownership information (“BOI”) report with FinCEN identifying information about the Reporting Company and each individual who directly or indirectly exercises substantial control or owns or controls 25 percent or more of the ownership interests of a Reporting Company (each, a “Beneficial Owner”).

    FinCEN has also begun accepting BOI reports from Reporting Companies and FinCEN Identifier applications from individuals seeking to obtain a FinCEN Identifier.[3]

    For additional information on the BOI Rule and BOI report filing obligations, please see our prior Alerts: (1) “The Corporate Transparency Act: Key Considerations for Compliance With the Beneficial Ownership Reporting Rule,” available here; and (2) “The Corporate Transparency Act: The Private Funds Guide to Compliance With the Beneficial Ownership Reporting Rule,” available here. 

    Filing Deadlines.

    • Existing Reporting Companies – A Reporting Company formed or registered before Jan. 1, 2024, must file an initial BOI report by Jan. 1, 2025.
    • New Reporting Companies – A Reporting Company formed or registered on or after Jan. 1, 2024, but before Jan. 1, 2025, must file an initial BOI report within 90 days of formation or registration. A Reporting Company formed or registered on or after Jan. 1, 2025, must file an initial BOI report within 30 days of formation or registration.
    • Updated/Corrected BOI Reports – A Reporting Company must submit updated/corrected BOI reports within 30 days of (i) any change to the information previously reported in the BOI report regarding the Reporting Company or its Beneficial Owners; or (ii) becoming aware (or having reason to know) of an inaccuracy regarding the information previously reported in the BOI report.[4]

    BOI Reports.

    Reporting Companies can prepare and submit an initial BOI report by either uploading a PDF version of it or completing it online. BOI Reports can be filed, updated or corrected through FinCEN’s BOI E-Filing system, which is accessible here: https://boiefiling.fincen.gov/. The PDF version of the BOI report can be downloaded, saved periodically as it is being completed and then uploaded to the BOI E-Filing System once finalized.[5] The online version of the BOI report can be prepared and submitted directly in the BOI E-Filing System.[6] Regardless of the filing option chosen, a BOI report transcript evidencing submission of the BOI report can be downloaded by the filer for recordkeeping purposes.

    FinCEN Identifier Applications.

    FinCEN Identifier applications can be filed, updated or corrected through a separate FinCEN webpage, which is accessible here: https://fincenid.fincen.gov/landing.[7] FinCEN Identifier applications may only be submitted online, and cannot be submitted via a PDF upload. In order to access the FinCEN webpage providing access to the FinCEN Identifier application, individuals must first sign in or create an account with “Login.Gov” and provide the required information. Obtaining a FinCEN Identifier is optional.

    Authored by Melissa G.R. Goldstein, Michael S. Didiuk, Betty Santangelo, Jessica Romano, Kyle B. Hendrix and Jonice Q. Jackson.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] Financial Crimes Enforcement Network, Beneficial Ownership Information Reporting Requirements, 87 Fed. Reg. 59.498 (Sept. 30, 2022), available here.

    [2] For more information regarding the CTA and AML Act generally, please see our prior Alert “Passage of Anti-Money Laundering Act of 2020 Includes Comprehensive BSA/AML Reform Measures.”

    [3] A FinCEN Identifier is a unique identifying number that FinCEN will issue to a Reporting Company or individual, such as a Beneficial Owner or individuals involved in the Reporting Company’s formation and/or registration to do business in the US (“Company Applicant”), which may be provided to FinCEN in lieu of the identifying information required of the Reporting Company or individual on a BOI report. Please see our prior Alerts on the BOI Rule and BOI report filing obligations linked herein for further information on who is considered a Beneficial Owner or Company Applicant.

    [4] Reporting Companies are not required to update previously reported information about their Company Applicants, but are required to correct any inaccurate information previously reported about their Company Applicants.

    [5] The PDF version of the BOI report form can be downloaded by selecting “Prepare BOIR” here.

    [6] The online version of the BOI report form can be accessed here.

    [7] Reporting Companies can obtain a FinCEN Identifier by checking a box on their BOI report.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    Jonice Q. Jackson

    Associate

    Washington, DC

    More insights

  • New ONC Final Rule Expands Information Blocking Regulatory Exceptions

    New ONC Final Rule Expands Information Blocking Regulatory Exceptions

    CLIENT ALERT / INFORMATION BLOCKING

    New ONC Final Rule Expands Information Blocking Regulatory Exceptions

    January 3, 2024

    Read time: 14 min

    Key takeaways
    Overview

    On December 13, 2023, the US Department of Health and Human Services (HHS) Office of the National Coordinator for Health Information Technology (ONC) issued the Health Data, Technology, and Interoperability: Certification Program Updates, Algorithm Transparency, and Information Sharing (HTI-1) final rule to update ONC Health IT Certification Program requirements and amend the information blocking regulations that ONC issued under the 21st Century Cures Act (Cures Act). The HTI-1 final rule substantially finalizes policies that ONC proposed in the HTI-1 proposed rule. This On the Subject discusses the final rule’s information blocking provisions, which are intended to support the sharing of electronic health information (EHI), but also include new and expanded exceptions to the information blocking prohibition applicable to health IT developers of certified health IT (certified health IT developers), health information network or health information exchanges (HIN/HIEs) and health care providers (collectively, actors). The HTI-1 final rule becomes effective 30 days after publication of the final rule in the Federal Register.

    We will release separate publications discussing ONC’s changes to the certification criteria and standards. For more information about ONC’s final information blocking regulations adopted in 2020, see our Special Report.

    In depth

    Key Changes to the Information Blocking Regulations

    • Updated scope of entities that may qualify as certified health IT developers under a new definition for what activities constitute “offering health IT” (with specific discussion about health IT donation and subsidized supply arrangements).
    • New information blocking exception for actors that fulfill requests for EHI through the Trusted Exchange Framework and Common Agreement (TEFCA) when the requestor is connected through TEFCA for the EHI they seek.
    • Revised infeasibility exception with two new conditions that apply to certain situations when an actor is asked to allow a third party to modify the EHI and when an actor cannot fulfill EHI requests after offering at least two alternative, interoperable manners for EHI access, exchange or use.

    Information Blocking Prohibition

    Under the regulations adopted by ONC in 2020, information blocking means a practice that, except as required by law or covered by an exception adopted by ONC, is likely to interfere with access, exchange or use of EHI and meets one of the following criteria:

    • If conducted by a certified health IT developer or HIN/HIE, such developer or HIN/HIE knows, or should know, is likely to interfere with, prevent or materially discourage access, exchange or use of EHI.
    • If conducted by a health care provider, the provider knows the practice is unreasonable and is likely to interfere with, prevent or materially discourage access, exchange or use of EHI.

    For an initial period (before October 6, 2022), the EHI within the definition of information blocking was limited to the data elements represented in the US Core Data for Interoperability version 1 standard. Since October 6, 2022, EHI for purposes of the information blocking definition has meant all protected health information to the extent it would be included in an electronic designated record set as such terms are defined by the Health Insurance Portability and Accountability Act (HIPAA). The HTI-1 final rule did not change the current definition but did remove the now-obsolete language that applied prior to October 6, 2022.

    Definitions of “Certified Health IT Developer” and “Offer Health IT”

    The certified health IT developer category of actors includes individuals or entities that “offer” certified health IT, but do not themselves develop certified health IT or take responsibility for the certification of health IT under the Health IT Certification Program.

    The HTI-1 proposed rule included a proposed definition of “offer health IT” to clarify what arrangements would cause an individual or entity to become a certified health IT developer. The HTI-1 final rule adopts substantially the same definition as proposed but with wording changes intended to improve clarity. As finalized, offer health IT means to hold out for sale, resale, license, or relicense or to sell, resell, license, relicense or otherwise provide or supply health IT that includes one or more certified health IT modules for deployment by or for other individuals or entities except for certain excluded arrangements.

    The excluded arrangements that would not constitute an offer are certain:

    • Electronic health record (EHR) and other health IT cost donation and other funding subsidy arrangements, provided the individual or entity offers and makes the subsidy without condition(s) limiting the interoperability or use of the technology to access, exchange or use EHI for any lawful purpose.
    • Health IT implementation and use activities conducted by an individual or entity, such as issuing login credentials.
    • Consulting and legal services, including legal services furnished by outside counsel and health IT consultant assistance selection, implementation and use consulting services.
    • Comprehensive and predominantly non-health IT clinician practice or other health care provider administrative or operations management services.

    The exclusion for health IT donation and funding subsidy arrangements is potentially valuable for health systems and other health care providers that subsidize independent physician practices’ and hospitals’ purchase or license of certified EHRs under the Stark Law’s EHR donation exception and the Anti-Kickback Statute’s EHR donation safe harbor. However, ONC states in the preamble that the exclusion from the offer health IT definition would not apply when an actor licenses or otherwise provides a health IT item or service itself to a recipient.

    The scope of the definition (including its exclusions) is important for health systems and other health care delivery organizations that may operate as a health care provider category of actor in most cases, but potentially act as a certified health IT developer actor in other instances by offering health IT to third parties. The category of actor impacts the knowledge standard under the information definition and the potential liability for information blocking violations. If the subsidizing providers are deemed to be certified health IT developers as offerors, they can be held liable for civil monetary penalties for any information blocking under the Cures Act. For more information about the final rule implementing the Cures Act provisions authorizing the HHS Office of Inspector General to impose civil monetary penalties for information blocking violations, see our Special Report. If the subsidizing providers are instead health care provider actors, they can be held liable for appropriate disincentives after HHS finalizes its appropriate disincentives proposed rule. For more information about HHS’s appropriate disincentives proposed rule, see our On the Subject.

    Expansion of the Infeasibility Exception

    The information blocking regulations include the infeasibility exception to allow an actor’s practice of denying a request to access, exchange or use EHI due to the infeasibility of the request, provided that both of the following apply:

    • The actor meets one of the exception’s conditions for different types of infeasibility.
    • The actor provides to the requestor in writing the reasons why the request is infeasible within 10 business days of receiving the request.

    The final rule amends the uncontrollable events condition in the infeasibility exception and adds two new conditions: one to allow an actor to deny a third party seeking modification use of EHI; and a second to allow an offer to deny a request for access, exchange or use after exhausting alternative manners offered under the manner exception. The final rule does not change the previously finalized conditions for segmentation and infeasibility under the circumstances.

    Uncontrollable Events Condition

    The uncontrollable events condition permits an actor’s practice of not fulfilling a request to access, exchange or use EHI that is infeasible for the actor to fulfill as a result of an event (e.g., a disaster or public health emergency) listed in the condition. The final rule revises the text of the condition to clarify that the mere fact that an uncontrollable event occurred is not sufficient for an actor to meet the condition. Instead, there must be a causal connection between the actor’s inability to fulfill a request and the uncontrollable event.

    Third Party Seeking a Modification Use Condition

    ONC finalized a new infeasibility condition that allows an actor to deny a request to provide the ability for a third party (or its application or other technology) to modify (e.g., create, write or delete) EHI maintained by or for a health care provider or other entity that has deployed health IT, provided that the request is not from a health care provider requesting such use from an actor that is its business associate (as defined by HIPAA). The final condition is the same as ONC’s proposed condition except for a non-substantive editorial change to shorten the text. The new condition addresses concerns by some certified health IT developers and other actors that there are not established standards for data modification use cases and that the modification of EHI by third parties may cause data integrity and security issues.

    Manner Exception Exhausted Condition

    ONC finalized a new manner exception exhausted condition under the infeasibility exception that permits an actor to deny a request for access, exchange or use of EHI after offering at least two alternative manners in accordance with the Content and Manner Exception (which ONC renamed the “Manner Exception” and to which ONC made technical amendments). According to the HTI-1 final rule preamble, ONC intends for the new condition to address some actors’ concerns about requests that require an actor to divert substantial technical, human or financial resources toward “new, unique or unusual manners of supporting access, exchange or use of EHI” and away from scalable, consensus standards-based solutions.

    On the other hand, ONC appears less receptive to concerns of third-party application developers and software-enabled or data-enabled service providers that some actors unfairly make available nonstandard application programming interfaces (APIs) and other interoperability elements to preferred requestors while denying substantially the same interoperability element to requestors that have developed competitive products or are otherwise disfavored.

    To satisfy the new manner exception exhausted condition, the actor must be unable to fulfill a request based on the following three factors:

    • The actor could not reach agreement with a requestor in accordance with the manner requested or was technically unable to fulfill a request for EHI in the manner requested.
    • The actor offered at least two alternative manners in accordance with the alternative manner prong of the manner exception, one of which must use either technology certified to standard(s) adopted by ONC under the Health IT Certification Program (g., certified API technology) or content and transport standards published by the federal government or a standards development organization accredited by the American National Standards Institute.
    • The actor does not provide the same access, exchange or use of the requested EHI to a substantial number of individuals or entities that are similarly situated to the requester. ONC states that this third factor is intended to prevent actors from misusing the manner exhausted condition to avoid supplying some requestors with manners of access, exchange or use that are generally available (rather than new, unique or unusual). However, ONC declines to define “substantial number” to allow for what ONC deems an “appropriate amount” of flexibility for various actors who may have very different numbers of customers or requestors. In response to comments, ONC states that calculating the percentage of customers using the same manner “may be helpful” and it believes that “‘substantial number’ is flexible enough to include as few as one customer, when appropriate, and as many as all of a given actor’s customers.” Inevitably, the meaning of substantial number will be in the eye of the beholder, such that requestors will expect their requests to be fulfilled in the manner requested if any of their competitors (or other arguably similarly situated requestors) receive the same manner, while some actors may choose to create a high threshold for what constitutes a substantial number when they do not want to provide access, exchange or use in a certain manner to a particular requestor.

    The manner exception exhausted condition also provides that in determining whether a requestor is similarly situated for purposes of the condition, an actor must not discriminate based on the following criteria:

    • Whether the requestor is a patient, member or other individual as defined by HIPAA.
    • The health care provider type and size.
    • Whether the requestor is a competitor of the actor or whether providing such access, exchange or use would facilitate competition with the actor.

    The prohibition on delineating entities based on size and type contrasts with the fees and licensing exceptions frameworks, which would permit groupings of similarly situated customers based on size and type for purposes of administering costs and licensing terms.

    TEFCA Exception

    The HTI-1 final rule includes a new TEFCA manner exception that allows an actor to limit the manner in which it fulfills a request to access, exchange or use EHI to only via TEFCA. The final exception is a standalone exception instead of the proposed rule’s proposed manner condition to the manner exception and includes some substantive changes in response to comments to the proposed rule.

    TEFCA originates from Section 4003 of the Cures Act, which required ONC to convene stakeholders to develop or support a national trusted exchange framework and common agreement for the exchange of health information between health information networks. Over the last several years, ONC has worked with stakeholders and its recognized coordinating entity, the Sequoia Project, to develop the Common Agreement for Nationwide Interoperability, the Qualified Health Information Network Technical Framework and other framework documents. Through its framework documents, TEFCA outlines a common set of principles, terms and conditions to enable nationwide exchange of EHI. On December 12, 2023, the first Qualified Health Information Networks (QHINs) were designated by The Sequoia Project on behalf of ONC, marking the start of information exchange via TEFCA.

    Under the TEFCA manner exception, an actor’s practice of limiting the manner in which it fulfills a request for access, exchange or use of EHI to only via TEFCA will not be considered information blocking when the practice meets the following conditions:

    • The actor and requestor are both part of TEFCA. Unlike the proposed rule, an actor is not required to check an available directory of TEFCA QHINs, participants and sub-participants. Instead, actors can determine whether requestors are enrolled in TEFCA through regular business interactions. In the final rule preamble, ONC states its policy interest in promoting interoperability through TEFCA and intends for this new exception to incentivize TEFCA participation. However, ONC acknowledges that not all entities will be ready, willing or able to join TEFCA.
    • The requestor is capable of such access, exchange or use of the requested EHI from the actor via TEFCA. If an actor is capable of providing access, exchange or use of some, but not all, of the requested EHI via TEFCA, the TEFCA exception can cover the EHI that the actor is capable of providing and the requestor is capable of accessing, exchanging or using via TEFCA. The actor could then provide the remaining EHI in a different manner, such as by using any of the alternative manners in the manner exception or by addressing the request through other methods or applicable information blocking exceptions.
    • The requestor does not seek to access, exchange or use EHI via the API standards (essentially Fast Healthcare Interoperability Resources (HL7 FHIR)-based standards) adopted by ONC or another version of those standards approved pursuant to the Standards Version Advancement Process under the Health IT Certification Program. When a requestor seeks to access EHI via such standards, the TEFCA manner exception is unavailable to the actor receiving such request.
    • Any fees charged by the actor in relation to fulfilling the request to satisfy the fees exception and any license of interoperability elements in relation to fulfilling the request to satisfy the licensing exception.

    ACTION ITEMS

    The HTI-1 final rule will have a significant impact on the information sharing activities of a broad cross-section of the health care industry. Impacted organizations should consider taking the following steps in response to the final rule:

    All Actors (Health Care Providers, Certified Health IT Developers, HIN/HIEs)

    • Consider adopting or updating policies and procedures for responding to requests to access, exchange or use EHI from persons other than the individual who is the subject of the EHI to reflect the following:
      • The manner exception exhausted condition of the infeasibility exception
      • If applicable, the new TEFCA manner exception.
    • Consider the benefits and limitations of becoming a TEFCA QHIN, participant or sub-participant in light of the TEFCA manner exception.

    Certified Health IT Developers and HIN/HIEs

    • Consider adopting new procedures for requests that involve the creation, deletion or other modification of EHI to reflect the new third party seeking “modification use” condition of the infeasibility exception.

    Health Care Providers

    • Review any EHR donation and funding subsidy agreements to determine whether any provisions could be considered by regulators as a condition limiting the interoperability or use of the technology to access, exchange or use EHI for any lawful purpose and, if so, consider removing or modifying the provisions to mitigate the risk of being deemed a certified health IT developer actor.

    If you have questions about how the final rule affects your organization, contact your regular McDermott lawyer or any of the authors of this On the Subject.

    Authors

    Daniel F. Gottlieb

    Partner

    Chicago

    James A. Cannatti III

    Partner

    Washington, DC

    Karen S. Sealander

    Counsel

    Washington, DC

    More insights

  • Mobility@McDermott: Monthly Update (12/2023)

    Mobility@McDermott: Monthly Update (12/2023)

    ARTICLE / CLIENT ALERT

    Mobility@McDermott: Monthly Update (12/2023)

    January 3, 2024

    Read time: 8 min

    Key takeaways
    Overview

    1. European Court of Justice rules on withdrawal rights regarding vehicle financing and leasing

    In a judgment released on 21 December 2023, the European Court of Justice (“ECJ”) further clarified the requirements for consumer withdrawal rights in connection with vehicle credit and leasing agreements.

    The ECJ ruling came in response to three cases originally brought before the district court of Ravensburg, Germany, involving various captive banks that had financed the purchase or the lease of vehicles. In one case, a consumer had entered into a vehicle leasing agreement while on the premises of a car dealership after discussing the contract in detail with a dealership employee. In the other two cases, a car dealership had brokered the financing agreements between the captive bank and consumers. In all three cases, the consumers withdrew from their contracts months or years after they had been concluded, in one case even after the loan had already been repaid in full, claiming that they had not been properly informed of their rights.

    The ECJ has now ruled that even if a leasing agreement with mileage allowance was to be considered a “distance contract” or an “off-premises contract”, the exception from the right of withdrawal relating to car rental services coupled with a specific date or period of performance can also apply to leasing agreements with a duration of 24 months where the main purpose of that agreement is to allow the consumer to use a vehicle for the specific period of time stipulated in that agreement, in return for the regular payment of sums of money. Therefore, regardless of how such a leasing agreement is concluded, consumers would never have a right of withdrawal (see sec. 312g para. 2 no. 9 German Civil Code (“BGB”)).

    In its reasoning, the ECJ emphasised that the customer had customised the leased vehicle and pointed out that, in the event of a withdrawal, the bank might not be able to put the vehicle to another equivalent use for the originally planned leasing period. It is therefore not entirely clear whether the ECJ’s decision also applies to leases of pre-configured (or even used) vehicles. The EU Directive 2011/83 which sets out the exception for vehicle rentals does not specify that the exception only applies to vehicles specifically customised for the lessee.

    Helpful for other scenarios is the ECJ ruling on a right of withdrawal for contracts concluded as a “distance contract” because they are only concluded by means of “distance communication” (see sec. 312c BGB). The ECJ ruled that even if a leasing contract is concluded by means of distance communication, it is not to be considered a distance contract if it is preceded by negotiations during which the consumer and someone acting on behalf of or in the name of the (captive) bank, such as in the present case the dealership’s employee, were both physically present and negotiated and shared information in relation to the contract, including with respect to key elements such as duration and monthly payments were discussed.

    While the lease agreement was therefore not a “distance contract”, it could have been an “off-premises contract” (see sec. 312b BGB). In its judgment, the ECJ clarified that where a contract is concluded on the premises of an intermediary acting in the name of or on behalf of a bank, it is not concluded “off-premises”, provided that the consumer, as an average consumer could have expected to be solicited by that intermediary for the purposes of the negotiation and conclusion of a contract with the bank and provided that such consumer could also easily have understood that the intermediary was acting in the name or on behalf of that trader.

    For financing agreements, the ECJ ruled that consumers can exercise their right of withdrawal even months after the conclusion of the contract if they have not been properly informed of their rights. However, consumers cannot exercise their right of withdrawal once the loan has been repaid in full.

    Relevant for: Finance providers, manufacturers.

    Further details here (in English).

    2. German government abruptly stops subsidies for electric vehicles

    In a move that came as a surprise to many, the German government has ended subsidies for electric vehicles. On 16 December, it was announced that the last day to apply for subsidies would be the following Sunday, 17 December as the funds allocated for the subsidy would not be replenished.
    Previously, the German government had offered electric vehicle holders a subsidy of up to EUR 4,500, depending on the sticker price of the vehicle. The subsidy was originally scheduled to continue in 2024. Because vehicle registration was a prerequisite for receiving the subsidy, consumers had to first purchase or lease a vehicle before they could apply for and receive the subsidy. In most cases, vehicle holders bear the risk of not being able to reclaim the subsidy under their lease or finance agreements.

    Following the abrupt end of the subsidy, many OEMs have announced that they will reimburse their customers for the subsidy in 2023.

    Relevant for: Manufacturers, finance providers, mobility providers.

    Further details here (available only in German).

    3. EU reaches political agreement on Artificial Intelligence regulation

    The European Union has reached a political agreement on a landmark bill to regulate artificial intelligence. After intense debate, the so-called “trilogue” between the European Commission, the Council and the European Parliament has reached a political agreement on the content of the bill. This agreement will now be translated into legislation.

    The intention behind the AI Act is to regulate artificial intelligence based on the potential of each category of AI to cause harm. One of the most heavily debated aspects of the bill was biometric surveillance. The use of this technology will now to be allowed for the targeted identification of individuals on a case-by-case basis when there is an imminent threat to life and limb. The subsequent use of biometric data collected in public spaces is generally permitted.

    The definition of artificial intelligence used in the bill was debated until the very last minute. It now defines AI as a “machine-based system that generates results such as predictions, content, recommendations or decisions from inputs for explicit or implicit goals that can have an impact on physical or virtual environments,” which is broader than some of the alternative proposals. The AI Act is expected to have an impact on the entire lifecycle of vehicles, including with respect to autonomous driving and even after-sales services when AI is used to determine maintenance intervals, for example.

    The trilogue will now finalise the details of the regulation which is expected to take about two months. After that, the general guidelines will have to be converted into standards that can be applied in practice. This is expected to take one to two years. According to the provisional agreement, there will be a two-year period after the entry into force of the AI Act before it is applied.

    Relevant for: Manufacturers.

    Further details here (in English).

    4. European Parliament endorses “Right to Repair” legislation

    On 21 November, the European Parliament endorsed by a large majority a draft law on the “right to repair”.

    Under the proposal, consumers will have the right to request repair of products such as washing machines, vacuum cleaners, smartphones and bicycles after the warranty has expired. Online platforms are envisaged to be set up to help consumers find local repair shops. The legislation also aims to make all spare parts available to independent repair shops, refurbishers and end customers at a reasonable cost to encourage the repair of goods.

    As already mentioned in our November update, motor vehicles are – contrary to the original proposal – not included in the scope of the proposed legislation.

    As the next step, the parliament will negotiate the proposal with the Council.

    Further details here (in English).

    5. EU reaches agreement on broad Supply Chain Act

    The Council and the European Parliament reached a provisional agreement on the Corporate Sustainability Due Diligence Directive (“CSDDD”) on 14 December 2023. The CSDDD aims to improve the protection of both the environment and human rights around the world. It sets out obligations for large companies to mitigate the risks in this area, both in their own operations, with respect to their subsidiaries and also in relation to their supply chain.

    The CSDDD applies to companies with more than 500 employees and a worldwide net turn-over of more than EUR 150 million. Non-EU companies may also fall within the scope of the CSDDD if their net turnover generated within the EU exceeds EUR 150 million. The CSDDD will also apply to smaller companies in certain sectors such as mineral resources, construction and agriculture. To ensure full transparency, the EU Commission will publish a list of all non-EU companies to which the CSDDD applies.

    While the CSDDD will facilitate civil liability claims brought forward by those affected by climate change, it will also provide for fines up to five percent of a company’s net turnover for violations.

    The provisional agreement between the Council and the European Parliament must now be endorsed and formally adopted by both institutions.

    Relevant for: All companies.

    Further details here (in English).

    In depth
    Authors

    Max Küttner

    Associate

    Düsseldorf

    More insights

  • Private Equity Update: Final Merger Guidelines Released

    Private Equity Update: Final Merger Guidelines Released

    ARTICLE / CLIENT ALERT

    Private Equity Update: Final Merger Guidelines Released

    January 2, 2024

    Read time: 12 min

    Key takeaways
    Overview

    What happened?

    The Antitrust Division of the Department of Justice (“DOJ”) and the Federal Trade Commission (“FTC”) jointly released the 2023 Draft Merger Guidelines (“Draft Guidelines”) on July 19, 2023. Although the Draft Guidelines were touted as “business-model agnostic,” we reported in our previous Alert several issues of potential concern for the private equity industry, including increased scrutiny of serial or roll-up acquisitions, transactions resulting in partial control or common ownership and board appointments.

    On Dec. 18, 2023, the agencies released the final 2023 Merger Guidelines (“Final Guidelines”), which modify the Draft Guidelines to address comments from the public, as well as feedback received during three Merger Guidelines Workshops. The Final Guidelines replace both the 2010 Horizontal Merger Guidelines and the 2020 Vertical Merger Guidelines and are effective immediately.

    The changes reflected in the Final Guidelines are minimal, and no changes were made to the sections most relevant to private equity firms that we discussed in our previous Alert.

    What changes did the Final Guidelines make to the Draft Guidelines?

    Even the more significant changes reflected in the Final Guidelines are more form than substance. The Final Guidelines reduce the number of analytical frameworks, termed “Guidelines” by the agencies, from 13 to 11 (although the substance of the deleted Guidelines is incorporated elsewhere[1]), soften somewhat the prescriptive language of the Guidelines,[2] clarify that all Guidelines can be rebutted or disproved,[3] and reincorporate the economic and evidentiary analyses (previously relegated to the appendices) into the main text.[4]

    The final 11 Guidelines are as follows:

    1. Mergers raise a presumption of illegality when they significantly increase concentration in a highly concentrated market.
    2. Mergers can violate the law when they eliminate substantial competition.
    3. Mergers can violate the law when they increase the risk of coordination.
    4. Mergers can violate the law when they eliminate a potential entrant in a concentrated market.
    5. Mergers can violate the law when they create a firm that may limit access to products or services that its rivals use to compete.
    6. Mergers can violate the law when they entrench or extend a dominant position.
    7. When an industry undergoes a trend toward consolidation, the agencies consider whether it increases the risk a merger may substantially lessen competition or tend to create a monopoly.
    8. When a merger is part of a series of multiple acquisitions, the agencies may examine the whole series.
    9. When the merger involves a multi-sided platform, the agencies examine competition between platforms, on a platform or to displace a platform.[5]
    10. When a merger involves competing buyers, the agencies examine whether it may substantially lessen competition for workers, creators, suppliers or other providers.
    11. When an acquisition involves partial ownership or minority interests, the agencies examine its impact on competition.

    The Final Guidelines state that Guidelines 1-6 describe distinct frameworks the agencies use “to identify that a merger raises prima facie concerns,” and Guidelines 7-11 explain how to apply those frameworks in specific settings. The Final Guidelines also signal more openness to rebuttal evidence than the Draft Guidelines, clarifying that “[i]n all of these situations, the Agencies will also examine relevant evidence to determine if it disproves or rebuts the prima facie case and shows that the merger does not in fact threaten to substantially lessen competition or tend to create a monopoly.”

    What do the Final Guidelines mean for private equity?

    Both the FTC and the DOJ repeatedly have sounded the alarm on private equity with regard to multiple issues: (1) private equity roll-up strategies; (2) the potential for private equity investments to chill competition (particularly in the healthcare space); (3) the lack of capacity or interest of private equity divestiture buyers in using divested assets to their full potential; (4) interlocking directorates (where a firm has representatives on the boards of competing companies); and (5) supposed filing deficiencies when private equity firms submit notifications pursuant to the Hart-Scott-Rodino (“HSR”) Act. We discuss each of these issues in more detail in our previous Alert on the Draft Guidelines.

    In that Alert, we also examine the portions of the Draft Guidelines most relevant – and concerning – to private equity. Those sections are largely unchanged in the Final Guidelines. Although they are not legally binding, the Final Guidelines represent the current views of the agencies toward mergers and acquisitions. Accordingly, and regardless of whether the courts ultimately will agree with the agencies’ interpretation of precedent (rejecting over four decades of jurisprudence based on the consumer welfare standard to do so), private equity firms should expect increased regulatory scrutiny of their transactions (even if not HSR-reportable), portfolios and board appointments. The top issues of concern are noted below and discussed more thoroughly in our previous Alert.

    • Roll-up acquisitions. When reviewing a transaction that is part of a roll-up strategy, the agencies may consider the cumulative effect on competition of the entire series of transactions, even if prior transactions were not HSR-reportable (Guideline 8). The agencies also may factor into their analysis an industry trend toward consolidation (Guideline 7). The agencies may examine the firm’s history and current or future strategic initiatives, and historical evidence may include the markets at issue and other markets.
    • Partial control or common ownership. The agencies may consider the competitive effect of acquisitions of less-than-full control (Guideline 11), such as those resulting in cross-ownership (where a market participant holds a non-controlling interest in a competitor) and common ownership (where individual investors hold non-controlling interests in competing firms). The Final Guidelines explicitly recognize that cross-ownership and common ownership “can reduce competition by softening firms’ incentives to compete, even absent any specific anticompetitive act or intent.”
    • Lowered market share and concentration thresholds. The Final Guidelines substantially lower the market share and concentration thresholds at which the agencies will presume a transaction substantially lessens competition or tends to create a monopoly, setting the threshold for presumed illegality at a level that would have been considered only potentially problematic under the previous 2010 Horizontal Merger Guidelines that they replace.[6] The Final Guidelines also retain the presumption of unlawfulness for any horizontal merger resulting in an increase of 100 HHI to a market share of over 30 percent. The formal market share presumption for vertical mergers was removed, but a footnote states that the agencies will infer a firm “has or is approaching monopoly power” when it would have a 50 percent or greater market share, and that mergers resulting in lower market shares may still substantially lessen competition, “particularly when [the] related product is important to its trading partners.”
    • Potential competition. The Final Guidelines back away from the Draft Guidelines’ proclamation that “[t]he antitrust laws reflect a preference for internal growth over acquisition,” but they note that, in general, “expansion into a concentrated market via internal growth rather than via acquisition benefits competition.” A merger may be illegal if it eliminates an “actual” potential competitor (e.g., where the possibility of entry or expansion by one or both parties would have resulted in new or increased competition in the market in the future) or a “perceived” potential competitor (e.g., where there is “current competitive pressure exerted on other market participants by the mere perception that one of the firms might enter”).
    • Competition for workers. The agencies may examine how deals will affect workers (e.g., a combined firm’s power over a labor market may lead to “lower wages or slow wage growth, worsen benefits or working conditions, or result in other degradations of workplace quality”). Under an administration that has prioritized enforcement against anticompetitive conduct in labor markets, the potential to lower prices to consumers through “efficiencies” or “synergies” resulting from the elimination of worker redundancy likely will carry little weight.
    • Higher bar for efficiencies arguments. The Final Guidelines significantly raise the evidentiary burden for efficiencies arguments. To be recognized as cognizable efficiencies, merging parties must satisfy all of the following criteria: (1) merger specificity,[7] (2) verifiability,[8] (3) prevents a reduction in competition,[9] and (4) not anticompetitive.[10] The efficiencies “must be of a nature, magnitude, and likelihood that no substantial lessening of competition is threatened by the merger in any relevant market.”

    Enforcement track record

    The Final Guidelines are consistent with the aggressive enforcement agenda of the agencies. These aggressive policies will be tested in court, and it remains to be seen whether courts will abandon over 40 years of jurisprudence based on the consumer welfare standard to embrace the agencies’ novel legal theories, particularly given the conservative majority on the Supreme Court.

    Although the agencies largely have come up short in litigated merger cases, with only one win in court and a number of deals called off due to the threat of litigation at the time the Draft Guidelines were published, they have since added a couple of notches in their belt. Just a few days before the Final Guidelines were issued (and just in time to be referenced multiple times in those guidelines), the Fifth Circuit issued an opinion siding with the FTC in its fight to stop Illumina, a biotech company specializing in gene-sequencing technology, from acquiring Grail, a manufacturer of cancer tests, leading to Illumina’s decision to divest Grail. This marks the FTC’s first successful litigation to block a vertical deal.

    Just the week before, Sanofi terminated a planned licensing agreement with Maze Therapeutics to develop treatments for Pompe Disease after the FTC announced it was seeking a preliminary injunction to block the deal. Also in the same timeframe, Adobe announced that it would abandon its proposed deal to take over Figma, a fellow competitor in the design software market, citing regulatory obstacles from the European Commission, the UK Competition and Markets Authority, as well as a potential challenge from the DOJ. The DOJ is awaiting the federal district judge’s ruling on its case to block JetBlue Airways’ proposed acquisition of Spirit Airlines.

    Another litigation to keep an eye on is the FTC’s suit against private equity firm Welsh Carson’s alleged scheme to monopolize the anesthesiology market in Texas through a roll-up strategy. Most recently, Welsh Carson filed a motion to dismiss in November. The case is an important barometer for private equity given that it is the first litigated challenge to serial acquisitions and also the first to target a minority private equity investor.

    What happens now?

    As a practical matter, the Final Guidelines have not moved the needle much in the regulatory landscape for private equity. The Final Guidelines largely reflect the agencies’ rhetoric in support of more aggressive merger enforcement and is consistent with their actions in and out of court since President Biden articulated the Administration’s broad antitrust policy in his July 2021 executive order. Private equity firms should continue to expect increased scrutiny of their transactions (even if not HSR-reportable), portfolios and board appointments by the DOJ and the FTC under this Administration.

    When considering a potential transaction (whether an acquisition of control or a partial acquisition), firms should engage antitrust counsel early in the process to assess antitrust risk, including analyzing competition and potential competition in horizontal, vertical and related markets, as well as evaluating potential labor market impacts. Antitrust counsel can help educate deal teams on document creation and the risks arising from, for example, overstating market share or improperly describing markets. In addition, given the substantially expanded HSR disclosure requirements proposed by the FTC in July (including provisions aimed at assessing serial acquisitions and identifying interlocking directorates), antitrust counsel can begin compiling the required information earlier in the process to minimize any HSR-related delays.

    Authored by Peter Jonathan Halasz and Ngoc Pham Hulbig.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] The former Guideline 6 (relating to vertical mergers) has been combined with other Guidelines, and the former “catch-all” Guideline 13 now is an unnumbered caveat in the text.

    [2] The Final Guidelines reflect changes to address commentators’ concerns over the Draft Guidelines’ apparent prohibition of certain types of transactions. For example, the final Guideline 3 softens the draft Guideline 3’s prescriptive statement that “mergers should not increase the risk of coordination” to a more traditional warning that “mergers can violate the law when they increase the risk of coordination.”

    [3] The Final Guidelines clarify that the merging parties may present evidence to rebut any theories of harm, including those based on the enumerated Guidelines. The agencies also emphasized in their press releases that the Final Guidelines “do not predetermine enforcement action.”

    [4] The Draft Guidelines were largely criticized for their bifurcation of legal doctrine from the underlying economics supporting an effects-based analysis, with the economic and evidentiary tools relegated to the appendices. The Final Guidelines reincorporate the economic analysis into the body of the text in a section discussing the “analytical, economic, and evidentiary tools the agencies use to evaluate facts, understand the risk of harm to competition, and define relevant markets.”

    [5] Platform businesses provide different products or services to two or more different groups or “sides” who may benefit from each other’s participation.

    [6] A merger is presumptively unlawful if it has a post-merger market concentration – measured by the Herfindahl-Hirschmann Index (“HHI”) – of 1,800 HHI and an increase in 100 HHI from pre-merger levels. Under these lower thresholds, in a market where seven participants have shares of 30 percent, five percent, 20 percent, 10 percent, five percent, five percent and five percent, a merger between the 10-percent player and a five-percent player would be presumed problematic.

    [7] The merger will produce substantial competitive benefits that could not be achieved without the merger under review. The agencies will consider alternatives such as organic growth of one of the firms, contracts between them, mergers with others, and a partial merger involving only those assets that give rise to the procompetitive efficiencies.

    [8] The benefits “are verifiable, and have been verified, using reliable methodology and evidence not dependent on the subjective predictions of the merging parties or their agents.”

    [9] The merging parties must demonstrate that the efficiencies will prevent the risk of a substantial lessening of competition in the relevant market, and not just benefit the parties themselves.

    [10] The efficiencies cannot result from the “anticompetitive worsening of terms for the merged firm’s trading partners.”


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Peter Jonathan Halasz

    Of Counsel

    New York – 919 Third Avenue

    More insights

  • The Corporate Transparency Act: Final Rule on Access to Beneficial Ownership Information

    The Corporate Transparency Act: Final Rule on Access to Beneficial Ownership Information

    ARTICLE / CLIENT ALERT

    The Corporate Transparency Act: Final Rule on Access to Beneficial Ownership Information

    January 2, 2024

    Read time: 13 min

    Key takeaways
    Overview

    On Dec. 21, 2023, to implement the Corporate Transparency Act (“CTA”),[1] the US Department of Treasury’s Financial Crimes Enforcement Network (“FinCEN”) issued a final rule (“Access Rule”)[2] providing access to reporting company and beneficial ownership information (“BOI”)[3] to: (1) several different types of government authorities; and (2) certain financial institutions to assist them in satisfying their anti-money laundering and counter terrorist financing (“AML/CFT”) obligations, but only with the consent of the reporting company. All BOI will be maintained in a private searchable database managed by FinCEN, called the Beneficial Ownership Secure System (“BOSS”). The Access Rule also imposes the security protocols for those with access to such BOI, and the penalties for failing to adhere to such security protocols or unauthorized disclosure or use of such BOI. The Access Rule goes into effect Feb. 20, 2024, and FinCEN will begin providing access to BOI information maintained in the BOSS in phases beginning with key federal agency users in 2024.

    Summarized below are key considerations regarding the Access Rule. While it largely tracks FinCEN’s original proposal issued on Dec. 16, 2022 (“Proposed Rule”),[4] and the text of the CTA, below are notable deviations from the Proposed Rule.

    Who will have access to BOI under the Access Rule and under what circumstances?

    The Access Rule authorizes FinCEN to disclose BOI to the following six general categories of recipients (collectively, “BOI Recipients”) in certain circumstances:

    1. US federal government agencies. The Access Rule permits FinCEN to disclose BOI to US federal agencies engaged in “national security, intelligence, or law enforcement activity,” such that the BOI would be in furtherance of those activities.
    2. US state, local and tribal government agencies (collectively with US federal government agencies, “Law Enforcement Requesters”). State, local and tribal law enforcement agencies will be authorized to access BOI if “a court of competent jurisdiction” rules that those agencies should be allowed access to that information. A “court of competent jurisdiction” is “any court with jurisdiction over the investigation for which a state, local or tribal law enforcement agency requests information” under the Access Rule.[5] In order to obtain BOI, state, local and tribal law enforcement agencies must “(1) certify to FinCEN that they have received authorization to seek BOI from a court of competent jurisdiction and that the BOI is relevant to a civil or criminal investigation, and (2) provide a description of the information the court has authorized the agency to seek.”[6]
    3. Foreign law enforcement agencies, judges, prosecutors, central authorities and competent authorities (collectively, “Foreign Requesters”). Foreign Requesters do not have open-ended query access to the database and must request access to BOI through intermediary US federal agencies. In requesting access, the Foreign Requesters must show that (1) the request is for assistance in a law enforcement investigation or prosecution, or for a national security or intelligence activity, that is authorized under the laws of the foreign country and (2) either (a) the request is made under an international treaty, agreement or convention or (b) the request is being made by law enforcement, judicial or prosecutorial authorities in a “trusted” foreign country. Notably, the Access Rule does not define “trusted” foreign country.
    4. Financial institutions (“FIs”) with customer due diligence (“CDD”) requirements for purposes of complying with AML/CFT regulations and safeguarding national security. The Access Rule provides for access to BOI to FIs that are subject to customer due diligence requirements under the Bank Secrecy Act implementing regulations (i.e., 31 C.F.R. § 1010.380) (“CDD Rule”), which currently consists of the following types of FIs: banks, brokers or dealers in securities, mutual funds, futures commission merchants and introducing brokers in commodities (collectively, “FI Requesters”). Other types of FIs, such as money services businesses and insurance companies, and other entities not yet subject to FinCEN’s regulations, such as registered investment advisers and the private funds they manage, will not have access to BOI unless there are separate regulations issued that would subject them to the CDD Rule.[7] Under the Access Rule, FI Requesters can only access BOI about a specific Reporting Company for purposes reasonably necessary to obtain or verify BOI of a legal entity customer (including a Reporting Company) to ensure compliance with AML/CFT legal requirements or prohibitions, or the safeguarding of US national security. The FI Requester must obtain and document consent from the Reporting Company prior to making the request to FinCEN.[8] The Access Rule, however, does not specify how an FI Requester should obtain consent from the Reporting Company, the form the consent must take, nor does it delineate procedures if a Reporting Company does not grant consent or later revokes consent. Such points will likely be addressed in a third rulemaking implementing the CTA.
    5. Federal functional regulators and other regulatory agencies, acting in a supervisory capacity to FI Requesters (“Regulator Requesters”).[9] The Access Rule authorizes Regulator Requesters to access BOI disclosed to FI Requesters (see paragraph 4 above) from either FinCEN or a FI Requester, provided that the Regulator Requesters can meet the following three conditions. First, the Regulator Requester must be “authorized by law to access, supervise, enforce, or otherwise determine the compliance of [a particular FI Requester] with its customer due diligence requirements under applicable law.” Second, the BOI requested to be disclosed must only be used to supervise, enforce, or otherwise determine the compliance of a particular FI Requester with its customer due diligence requirements under applicable law. Third, the Regulator Requester must “[enter] into an agreement with FinCEN to properly safeguard BOI.” Where a Regulator Requester is obtaining the information directly from the FI Requester, the FI Requester can rely on a statement from a Regulator Requester that it meets the three conditions.[10]
    6. US Department of the Treasury. Finally, certain officers or employees of Treasury, including its offices and bureaus, such as the Office of Foreign Assets Control, FinCEN and the Internal Revenue Service, will have broad access to BOI where the Secretary of the Treasury determines it necessary for such Treasury officers and employees to meet their official duties, including for tax administration.

    Significant changes in the Final Rule from the Proposed Rule

    While the Access Rule largely tracks the Proposed Rule, there are three notable deviations from the Proposed Rule, each of which is described below.

    1. Streamlined process for state, local and tribal law enforcement agencies to access BOI. The Access Rule provides for three changes to the process to be used by state, local and tribal law enforcement agencies obtaining BOI. Such agencies: (1) will only need a “‘court authorization’ to seek BOI from FinCEN as part of a civil or criminal investigation,” not a specific form of authorization, such as a court order;[11] (2) must certify that they have received the necessary court authorization and provide a description of the information the court has authorized the agency to seek rather than submit to FinCEN a copy of the court authorization received by the agency; and (3) will not be required to provide to FinCEN a written justification of the request because FinCEN will not review each state, local or tribal law enforcement request in advance of releasing the BOI but will audit and conduct oversight of such agencies’ searches for BOI to ensure that BOI is requested for authorized purposes by authorized recipients.[12]
    2. Reduced limitations on offshore access to BOI. Under the Access Rule, FI Requesters receiving BOI are not required to store such information in the US, but are prohibited from sending BOI to certain foreign jurisdictions and categories of jurisdictions, such as Russia, China, any jurisdiction designated as a state sponsor of terrorism and any jurisdiction that is subject to comprehensive sanctions under US law.[13] And “in order for FinCEN to monitor foreign government interest in obtaining BOI, the Access Rule requires that financial institutions notify FinCEN within three business days of receiving a demand from a foreign government for BOI obtained from FinCEN.”[14]
    3. Broadened scope of FI Requester access to BOI. The Access Rule adopts a broader interpretation of the phrase “customer due diligence requirements under applicable law” that allows FIs to use BOI for compliance with their AML programs, customer identification and verification, suspicious activity reporting obligations filing and sanctions, anti-fraud and anti-bribery compliance.[15] FI Requesters “can also use BOI to satisfy other requirements, so long as those requirements are designed to counter money laundering or the financing of terrorism or safeguard US national security, and so long as it is reasonably necessary to obtain or verify BOI of legal entity customers to satisfy those requirements.”[16] Use of BOI for general business purposes is not permitted.

    Safeguards for BOI

    BOI Recipients will be required to have standards and procedures for storing any BOI released by FinCEN in a secure system that will limit access to such information only to authorized personnel. Law Enforcement Requesters are required to enter into a memorandum of understanding with FinCEN specifying the standards, procedures and systems for protecting the security of BOI prior to that Law Enforcement Requester obtaining access to BOI. For FI Requesters to access BOI, they must “satisfy the requirement to safeguard BOI by applying the security and information handling procedures used to comply with Gramm-Leach-Bliley and its implementing regulations.”[17] These standards and procedures may be subject to audit, and BOI Recipients would have to maintain information about specific BOI searches or requests, such that the searches or requests could be reviewed by FinCEN.

    Penalties

    The CTA and the Access Rule make it unlawful to knowingly engage in an unauthorized disclosure or use of BOI obtained directly or indirectly through a BOI report submitted to FinCEN pursuant to the BOI reporting obligation[18], or an authorized disclosure made by FinCEN pursuant to the Access Rule. An “unauthorized use” of BOI would be accessing information without authorization and would include violating any BOI security safeguards or confidentiality requirements.[19]

    Any unauthorized disclosure or use of BOI may result in significant civil and criminal penalties.[20] In addition, any individual requester or requesting entity may be debarred or suspended by FinCEN for: (1) any failure to meet the requirements of the Access Rule; (2) if information is requested for an unlawful purpose, or (3) if other good cause exists.[21]

    Additional FinCEN guidance on the Access Rule

    1. Re-disclosure of BOI. Re-disclosure of BOI by BOI Recipients is generally prohibited. However, the Access Rule allows re-disclosure in the following specific circumstances: “[1] among officers, employees, agents, and contractors within a particular authorized recipient entity; [2] among FIs and their regulators, including qualifying SROs; [3] from intermediary Federal agencies to foreign requesters; [4] from specified authorized BOI recipient Federal agencies to courts of competent jurisdiction or parties to a civil or criminal proceeding; [5] from authorized BOI recipient agencies to prosecutors or for use in litigation related to the activity for which the requesting agency requested the information; and [6] by foreign authorities consistent with the international treaty, agreement, or convention under which BOI was received. FinCEN may also authorize the re-disclosure of BOI by an authorized recipient in other situations, so long as the re-disclosure is for an authorized purpose.”[22]
    2. Implementation of BOI access. FinCEN will begin providing access to BOI in phases beginning with a pilot program for key federal agency users in 2024. The second phase will include Treasury officials and certain other federal agencies engaged in law enforcement and national security activities that already have a memorandum of understanding in place to access Bank Secrecy Act information. The third and subsequent stages will call for access by additional federal agencies, state, local and tribal law enforcement agencies and FI Requesters and Regulator Requesters. FinCEN expects to provide additional details on the phased implementation approach in early 2024.[23]

    FinCEN will be issuing additional guidance on the Access Rule and is establishing a contact center that will be of assistance to BOI Recipients, which is expected to be operational by Jan. 1, 2024.

    FI Requestors should monitor future FinCEN guidance to ascertain whether or not they wish to take advantage of the Access Rule and seek BOI from FinCEN. To do that, they should determine whether access to BOI would facilitate their AML compliance efforts. If they determine to obtain access to BOI, they should implement proper safeguards to allow only authorized personnel to access BOI and update their procedures to obtain consent from Reporting Companies.

    The information in this Alert should be considered in conjunction with any applicable guidance that FinCEN may issue. Future FinCEN guidance could differ or add nuance to the information discussed above.

    Authored by Melissa G.R. Goldstein, Michael S. Didiuk, Betty Santangelo, Jessica Romano, Kyle B. Hendrix and Jonice Q. Jackson.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1]   For more information regarding the CTA please see our prior Alert “Passage of Anti-Money Laundering Act of 2020 Includes Comprehensive BSA/AML Reform Measures,” available here.

    [2]   FinCEN, Final Rule, Beneficial Ownership Information Access and Safeguards, 88 Fed. Reg. 88,732 (Dec. 22, 2023), available here and codified at 31 C.F.R. §§ 1010.950 and 1010.955. The Access Rule is the second of three rulemakings that will implement the CTA. The third rulemaking, which is still being drafted, will revise FinCEN’s customer due diligence rule to align it with the CTA.

    [3]   For more information on the BOI reporting obligation please see our prior Alerts: (1) “FinCEN Issues Final Rule Requiring Reporting of Beneficial Ownership Information,” available here; (2) “The Corporate Transparency Act: Key Considerations for Compliance With the Beneficial Ownership Reporting Rule,” available here and (3) “The Corporate Transparency Act: The Private Funds Guide to Compliance With the Beneficial Ownership Reporting Rule,” available here.

    [4]   FinCEN, Notice of Proposed Rulemaking, Beneficial Ownership Information Access and Safeguards, and Use of FinCEN Identifiers for Entities, 87 Fed. Reg. 77,404 (Dec. 16, 2022), available here. For more information on the Proposed Rule, please see our prior Alert: “FinCEN Issues Proposed Access Rule and Proposed Forms to Further Implement the CTA.”

    [5]   31 C.F.R. § 1010.955(b)(2)(i).

    [6]   The Access Rule, 88 Fed. Reg. at 88,748.

    [7]   FinCEN reserved the right to determine that access to BOI should be extended to other FIs at a later time. Id. at 88,757.

    [8]   Id. at 88,772.

    [9]   The Access Rule provides that the six Federal functional regulators that supervise Fis with customer due diligence obligations are the Board of Governors of the Federal Reserve System, the Office of the Comptroller of the Currency, the Federal Deposit Insurance Corporation, the National Credit Union Administration, the Securities and Exchange Commission and the Commodity Futures Trading Commission. The Access Rule also provides BOI access to any self-regulatory organization registered with or designated by a Federal functional regulator pursuant to Federal Statute, that supervises and enforces FI compliance with customer due diligence requirements, such as the Financial Industry Regulatory Authority (FINRA) or the National Futures Association (NFA).

    [10] A Regulator Requester also has the same access that Law Enforcement Requesters have if the Regulator Requester engages in civil law enforcement activities. The Access Rule, 88 Fed. Reg. at 88,745.

    [11] The Access Rule, 88 Fed. Reg. at 88,747.

    [12] Id. at 88,748.

    [13] Id. at 88,769; 31 C.F.R. § 1010.955(d)(2)(i).

    [14] The Access Rule, 88 Fed. Reg. at 88,769; 31 C.F.R. § 1010.955(d)(2)(ii)(B).

    [15] The Access Rule, 88 Fed. Reg. at 88,757. The Proposed Rule limited “customer due diligence requirements under applicable law” to compliance with the CDD Rule. See Proposed Rule, 87 Fed. Reg. at 77,415.

    [16] The Access Rule, 88 Fed. Reg. at 88,748.

    [17] Id. at 88,770.

    [18] Supra n.3.

    [19] 31 C.F.R. § 1010.955(f).

    [20] 31 U.S.C. § 5336(h)(3)(B) (authorizing a civil penalty of $500 per day for each violation that has not ceased or been remedied, criminal penalties of a fine of up to $250,000 or imprisonment for not more than five years, or both, and enhanced criminal penalties of a fine of up to $500,000 and up to 10 years’ imprisonment).

    [21] 31 C.F.R. § 1010.955(e)(3).

    [22] Financial Crimes Enforcement Network, Fact Sheet: Beneficial Ownership Information Access and Safeguards Final Rules (Dec. 21, 2022), available here.

    [23] Id.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    Jonice Q. Jackson

    Associate

    Washington, DC

    More insights

  • IRS Says Keep Those Class Exclusions Classy Under Long-Term, Part-Time Employee Rules

    IRS Says Keep Those Class Exclusions Classy Under Long-Term, Part-Time Employee Rules

    ARTICLE / CLIENT ALERT

    IRS Says Keep Those Class Exclusions Classy Under Long-Term, Part-Time Employee Rules

    December 28, 2023

    Read time: 5 min

    Key takeaways
    Overview

    In this series of articles, we explore the implications of the long-term, part-time employee rules under the SECURE Act and SECURE 2.0 and the impact those rules have on employers and their workforces. Read the first client alert, “Last-minute IRS guidance leaves little time for long-term, part-time employee changes.”

    Together, the SECURE Act and the SECURE 2.0 Act broaden the retirement plan minimum eligibility rules—i.e., the rules that govern how long employees can be asked to wait before joining an employer’s retirement plan—to ensure that long-term, part-time employees can participate in employer 401(k) and 403(b) plans.

    Historically, to avoid violating the tax code, employers could not require employees to work more than 1,000 hours of service in a designated 12-month period before allowing them to participate in company retirement plans. However, the new laws modify this rule for 401(k) plans and 403(b) plans. Specifically, the new rule requires employers that maintain such plans to provide employees who work at least 500 hours for three consecutive years (reduced to two years in 2025) and are age 21 or older the opportunity to make elective deferrals under their 401(k) plans beginning in 2024 and under their 403(b) plans beginning in 2025.

    This change has generated numerous questions about what employers need to do to comply with the new rule. Can an employer, for example, continue to exclude employees based on certain job-based classifications even if those employees would otherwise be eligible to participate in the plan by satisfying the long-term, part-time employee rules? The short answer is yes. However, employers should still revisit their existing eligibility rules and exclusions to ensure that those exclusions still make sense.

    In depth

    Most employers exclude some employees from their 401(k) plans and, to a lesser extent given the strict universal availability requirements, their 403(b) plans. Doing so has always been permissible as long as the exclusions are reasonable and nondiscriminatory. As a result, exclusions based on bona fide, job-based classifications are typically permitted. However, things get a little more complicated when that job-based classification relates to the amount of time someone spends working for the business.

    This is because the Internal Revenue Service (IRS) has indicated that it does not consider class-based exclusions of part-time, seasonal or temporary employees to be reasonable. Instead, the IRS views those exclusions as a proxy for imposing backdoor service-based conditions on plan participation that are not otherwise permitted under the tax code. Put another way, the IRS sees attempts to impose a class exclusion on these employees as a way to circumvent the rules that otherwise require employers to let employees in their plans after they perform a requisite period of service.

    The new long-term, part-time employee rules under the SECURE Act and the SECURE 2.0 Act do not change this. This means employers can still exclude employees from their plans based on job function or location as long as the exclusion represents a bona fide and nondiscriminatory class exclusion and is not a proxy for imposing an otherwise impermissible service condition. For example, if most part-time-type employees are performing the same job function or work at the same location, an employer could theoretically exclude all employees who perform that same job function or work at the same location from its 401(k) plan without violating the tax code’s minimum service rules (as long as the plan can still pass required nondiscrimination testing). But—and this is a big but—some IRS representatives have indicated that even criteria like job function and work location that are not service-based may still violate the tax code if they merely disguise an improper service rule.

    As a result, the new long-term, part-time employee rules have generated renewed interest in the application of the class exclusion rules, for example as they relate to groups like summer interns or co-op employees. This is especially true in situations where employers are using believed-to-be bona fide class exclusions but have also historically taken comfort in knowing the employees subject to any service-adjacent exclusions will never work more than 1,000 hours in a designated 12-month period. With the hours threshold for participation changing, it is as important as ever for employers to revisit their existing eligibility exclusions to ensure that they continue to be primarily job and not service-based.

    Authors

    Brian J. Tiemann

    Partner

    Chicago

    Haley M. Dow

    Associate

    Chicago

    More insights

  • Stark Law Changes for 2024: CMS Updates Designated Health Services Code List

    Stark Law Changes for 2024: CMS Updates Designated Health Services Code List

    ARTICLE / CLIENT ALERT

    Stark Law Changes for 2024: CMS Updates Designated Health Services Code List

    December 27, 2023

    Read time: 8 min

    Key takeaways
    Overview

    On November 29, 2023, the Centers for Medicare & Medicaid Services (CMS) published the 2024 annual update to the designated health services (DHS) Code List. This annual update includes important changes for Medicare providers who rely on the Code List to ensure financial relationships with physicians remain in compliance with the federal physician self-referral law (the Stark Law). Of particular note, CMS has clarified that certain definitive drug testing codes will be considered DHS.

    In depth

    BACKGROUND

    The Stark Law restricts financial relationships between a physician and any entity that furnishes and bills Medicare for DHS (a DHS Entity), and many of the most commonly used Stark Law exceptions implicitly rely on DHS Entities to appropriately identify the DHS such entities furnish. Accordingly, it is important for Medicare providers and suppliers to stay up to date on what CMS considers DHS.

    CMS annually publishes the Code List to specify certain categories of healthcare services that are considered DHS under the Stark Law. The Code List includes a subset of Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes that CMS considers DHS. This is the second year that CMS has elected to publish the annual update through its Code List website instead of publishing it in the Federal Register in connection with routine annual payment system updates (i.e., the Medicare Physician Fee Schedule rulemaking cycle). Comments on the Code List updates are due by December 29, 2023. 

    DIG DEEPER

    The Stark Law strictly limits financial relationships between physicians and DHS Entities that furnish “designated health services.” More specifically, the Stark Law prohibits physicians from referring patients to an entity for DHS covered by Medicare if the physician (or one of his or her immediate family members) has a financial relationship with the DHS Entity, unless an exception applies. The Stark Law also prohibits the DHS Entity from billing Medicare or any other person or entity for improperly referred DHS. A “financial relationship” is defined broadly to include any direct or indirect ownership or investment interest, and any direct or indirect compensation arrangement. If a Medicare provider or supplier bills for DHS that does not comply with a Stark Law exception, the DHS Entity may be subject to significant civil penalties and exposure under the federal False Claims Act.

    It is a critical element of Stark Law compliance for Medicare providers to know what codes and services are considered DHS. Many healthcare providers rely on Stark Law exceptions that require physicians to be compensated only for (or based on)those services that are not considered DHS or that otherwise require a provider to precisely identify the services furnished and billed by that provider that constitute DHS. These 10 categories of items and services are considered DHS under the Stark Law:

    1. Clinical laboratory services
    2. Physical and occupational therapy, and outpatient speech-language pathology (SLP) services (collectively, Outpatient Rehabilitation Services)
    3. Radiology and certain other imaging services
    4. Radiation therapy services and supplies
    5. Durable medical equipment and supplies
    6. Parenteral and enteral nutrients, equipment and supplies
    7. Prosthetics, orthotics, and prosthetic devices and supplies
    8. Home health services
    9. Outpatient prescription drugs
    10. Inpatient and outpatient hospital services

    THE CODE LIST

    Each category of DHS is defined by regulation. Helpfully, four DHS categories—clinical laboratory services, Outpatient Rehabilitation Services, radiology and other imaging services, and radiation therapy services and supplies—are defined by the Code List. However, the following categories of DHS are defined without regard to the Code List:

    1. Durable medical equipment and supplies
    2. Parenteral and enteral nutrients, equipment and supplies
    3. Prosthetics, orthotics, and prosthetic devices and supplies
    4. Home health services
    5. Outpatient prescription drugs
    6. Inpatient and outpatient hospital services

    For those categories of DHS that are defined by way of reference to the Code List, if a particular CPT or HCPCS code is not listed on the Code List, the service is not DHS under the Stark Law. For DHS categories that are defined without regard to the Code List, providers must independently verify whether a particular CPT or HCPCS code falls within the applicable DHS regulatory definition.

    While the Code List is helpful, it is not without its faults. In addition to identifying the CPT or HCPCS codes that are considered DHS within the four categories noted above, the Code List also includes details regarding the applicable codes that are eligible for use with the Stark Law exception for preventive screening tests and vaccines (found at 42 C.F.R. § 411.355(h)). Providers should also be aware that the Code List defines the majority of clinical laboratory services by way of reference to the 80000-series CPT codes only. Namely, instead of listing the codes individually as CMS does for the other DHS categories, providers are required to consult multiple other Medicare fee schedule files (including the Medicare Physician Fee Schedule and the Clinical Laboratory Fee Schedule files) to determine the CPT codes that fall within this series and are considered “clinical laboratory services” within the Stark Law’s regulatory definition. The Code List also explicitly lists certain lab services that are excluded from clinical laboratory services. These quirks mean that a simple cross-reference or comparison to the Code List is insufficient and generally incomplete. Finally, and as noted above, many healthcare providers do not realize that the Code List is not a comprehensive list of all codes that CMS considers DHS and that the Code List only covers four of the 10 DHS categories. As a result, providers often miss large swaths of DHS codes from the other six categories, or inappropriately flag excepted-DHS codes that are counterintuitively listed on the Code List.

    CMS ADDED DRUG TEST CODES, COVID-19 CODES TO DHS LIST

    In the latest iteration of the DHS Code List, most notably, CMS added certain laboratory services codes and updated the codes for certain COVID-19 services.

    Specifically, CMS added definitive drug testing laboratory services to the Code List. As opposed to screening tests, definitive drug testing is used to identify a specific drug and quantity in a patient. These codes are generally used to confirm and identify the presence or absence of specific drugs in patients who are undergoing treatment for pain management or substance use disorders. The addition of these testing codes to the Code List could dramatically increase the quantity of DHS furnished by certain types of providers, particularly substance use disorder, pain management and behavioral health providers. This could also subject certain providers, in particular in the behavioral health space, to the Stark Law, in addition to changing the percentage of DHS furnished by such providers beginning in calendar year (CY) 2024.

    COVID-19 vaccines and monoclonal antibody products are considered DHS and are included on the proposed Code List for 2024. However, in light of the expiration of certain public health programs related to COVID-19, CMS removed certain COVID-19 specimen collection and testing codes from the Code List. The COVID-19 vaccines and monoclonal antibody products remain eligible for the Stark Law exception for preventive screening tests and vaccines.

    Finally, CMS made other minor edits and updates to the radiation therapy and radiology services included on the Code List. CMS’s summary of the changes can be reviewed here.

    DHS CODE LIST PROCEDURAL CHANGES

    Updates to the Code List for CYs 2022 and earlier were published in the Federal Register as an addendum to the annual Medicare Physician Fee Schedule final rule.

    Beginning with the CY 2023 Code List, CMS is now only publishing updates to the Code List on its website (available at CMS List of DHS CPT/HCPCS Codes) near the end of each calendar year. CMS published the proposed 2024 Code List updates on November 28, 2023, and provided a scant 30-day period for healthcare providers to review and provide comments on the proposed changes.

    In response to the updated publication methodology and 2023 Code List updates, CMS received zero comments. The complete lack of comments or other feedback on the Code List updates last year suggests that stakeholders may not be fully aware that CMS has changed its process, or that they do not have sufficient notice to provide meaningful responses. For additional insight on substantive changes made to the services that are considered DHS by way of inclusion on the Code List, please view our earlier analysis in this On the Subject.

    TAKEAWAYS

    Providers should ensure that they carefully review and analyze the services they furnish on a regular basis, which should include, but cannot be limited to, reviewing the Code List.

    Separate from the Code List, there are annual updates to the CPT codes (published and maintained by the American Medical Association) and to the HCPCS code lists. As the CPT and HCPCS code sets are updated, retired and created, providers and practice administrators should be sure to review how these changes may affect which services furnished by providers are considered DHS. This requires consulting the regulatory definitions for the six categories of DHS that do not rely on the Code List.

    Providers subject to the Stark Law should also review CMS’s annual update to the Code List. The final Code List for CY 2024 will be published in January. To the extent that providers have comments or concerns with respect to this revised publication process, they should consider submitting comments, even if such comments are not provided to CMS by the December 29, 2023, deadline. Comments may be submitted here.

    Authors

    Caroline Reignley

    Partner

    Washington, DC

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Monica Wallace

    Partner

    Chicago

    More insights

  • Employment Update: New York State Governor Hochul Vetoes New York State Non-Compete Ban Bill

    Employment Update: New York State Governor Hochul Vetoes New York State Non-Compete Ban Bill

    ARTICLE / CLIENT ALERT

    Employment Update: New York State Governor Hochul Vetoes New York State Non-Compete Ban Bill

    December 26, 2023

    Read time: 4 min

    Key takeaways
    Overview

    On Dec. 22, 2023, New York State Governor Kathy Hochul vetoed a bill that would have prohibited all non-compete restrictions on New York-based employees (and certain service providers) and allowed them to recover civil damages from their employers who impermissibly imposed such restrictions. As discussed in more detail in our earlier Alert, if the bill had become law, New York would have been the fifth state to ban non-competes, joining California, North Dakota, Oklahoma and Minnesota (Minnesota being the last in 2023). Although New York’s legislature could override Gov. Hochul’s veto, it is considered highly unlikely – legislative veto overrides in New York are extremely rare.

    Gov. Hochul vetoed the bill after intense negotiations between legislative leaders and the Governor to find a compromise to limit the bill’s scope, such as imposing a non-compete ban on employees earning below a specified dollar threshold. The fact that neither side was willing to cede negotiation points suggests that the battle over non-competition legislation will continue into next year. In fact, the bill’s sponsor has vowed to reintroduce the bill next year.

    The veto of the 2023 bill should not lead to complacency. New York and other states may pass legislation limiting or prohibiting non-competes and similar restrictive covenants, increasingly courts are reviewing restrictive covenants more strictly and, as described in our Alert, the Federal Trade Commission is expected to take action to finalize its proposed federal non-compete prohibition in 2024.

    In light of the current environment, we are recommending that employers, including alternative investment managers that require their partners and employees to agree to restrictive covenants, consider revisiting their approach to restrictive covenants. For example, employers should consider:

    • Individually tailoring the terms of non-competition and non-solicitation restrictions based on an employee’s (or other service-provider’s) role and responsibilities and the employer’s actual needs;
    • Reviewing restrictive covenants for employees working remotely in other states, for compliance with applicable state laws;
    • Bolstering contractual obligations and policies to protect intellectual property;
    • Establishing deferred compensation and other arrangements that incentivize compliance with restrictive covenant obligations; and
    • Adopting senior-level plans (commonly referred to as “top hat plans”) that might sidestep any state (but not federal) limitations on non-competition and non-solicitation restrictions.

    We will continue to monitor and advise you of federal and state law developments affecting non-competes and are available to discuss practical approaches to preemptively address them.

    Authored by Mark E. Brossman, Ronald E. Richman, Ian L. Levin, Martin L. Schmelkin, Max Garfield and Adam B. Gartner.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

     

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Ian L. Levin

    Partner

    New York – 919 Third Avenue

    Martin L. Schmelkin

    Partner

    New York – 919 Third Avenue

    Max Garfield

    Partner

    New York – 919 Third Avenue

    Adam B. Gartner

    Special Counsel

    New York – 919 Third Avenue

    More insights

  • New Year, New Laws: California Healthcare Providers Subject to New Requirements in 2024

    New Year, New Laws: California Healthcare Providers Subject to New Requirements in 2024

    ARTICLE / REPORT

    New Year, New Laws: California Healthcare Providers Subject to New Requirements in 2024

    December 2023

    Read time: 2 min

    Overview

    The California legislature has created a lot of holiday homework for California healthcare providers, passing more than 50 new laws regulating a wide range of healthcare providers and healthcare business operations that apply to many areas of the state’s healthcare system. Many of these reforms become effective as we usher in the new year, and there are many updates healthcare providers and facilities should be aware of. We’ve summarized the laws you need to know and are ready to assist with compliance efforts.

    In depth
    Tabs

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    More insights
    Endnotes

  • Innovation in Financing: Where Are We Seeing Growth?

    Innovation in Financing: Where Are We Seeing Growth?

    ARTICLE / CLIENT ALERT

    Innovation in Financing: Where Are We Seeing Growth?

    December 2023

    Read time: 6 min

    Key takeaways
    Overview

    In November, we were pleased to once again host our annual European Health & Life Sciences Symposium in Paris. The event attracted a large number of healthcare professionals, investors and dealmakers to the Shangri-La Hotel for a series of insightful panel discussions, including a particularly interesting session on innovations in the financing market.

    The broader macro and geopolitical landscape has created a particularly challenging financing environment for investors in health and life sciences in 2023. Uncertainty and the higher cost of capital has driven lender reticence, resulting in a flight to quality borrowers and top-tier assets such that really high quality assets continue to transact at values largely unchanged but for others it is difficult to convince lenders to transact.

    In depth

    Meanwhile, cash-strapped biotechs have in many cases been forced to leverage relationships with big pharma to address liquidity. Cash is king in a financing environment such as we have observed over the last 18 months, and the biotech industry requires a lot of cash so it has had to adapt. For those companies unable to tap into big pharma, the alternative has been to streamline the business and prioritise core business lines.

    For lenders, the focus has been much more on downside risk in such an uncertain environment, so the assets in favour have been those with sustainable cashflows and the ability to create true growth. That has led to more activity in generics and well-positioned CDMOs, and an increased spotlight on relationships with management teams.

    Some of the lenders that joined us at the symposium spoke about the need for borrowers to be able to tell a clear and compelling story about their business, demonstrating track record and sharing data points to secure capital. Others talked about being laser-focused on business quality, looking harder than ever at gross margins and recurring revenues and digging deep into customer-level diligence to look at things like re-ordering patterns.

    Despite the pressure on balance sheets, lenders have done nothing to loosen their focus on the environmental, social and governance aspects of their investments, and our panellists talked about how ESG is a large (and growing) priority. Both sponsors and credit funds say LPs are still pushing them to be ESG-centric and lenders continue to look for ways to use financial and other incentives to drive impact.

    Ettore Scandale, partner with McDermott Will & Emery in Milan, says: “Outside of financial metrics, impact metrics are really important to lenders. Even those that are not Article 9 funds under the regulations are looking closely at ESG indicators during due diligence and are discussing them in depth during investment committee meetings.”

    He adds: “There is a clear focus across the market on having defined quarterly impact metrics that credit funds can report back to their LPs to demonstrate and follow the impact of their investments. Increasingly that is seen as a critical element of driving the return.”

    Moving into 2024, a number of challenges remain that will impact the demands for financing in our market in the year ahead. Chief amongst these is the lack of available venture capital to a lot of biotech and medtech companies that are yet to become EBITDA positive. That shortage of finance has impacted CMOs and other businesses in the complex biologics value chain, meaning many companies that service venture-backed companies are delaying projects and some platform businesses in that space are becoming single-asset companies.

    Another challenge noted by our speakers was the regulatory landscape, with changes such as the introduction of drug pricing policies in the US creating uncertainty for equity investors. With the pricing of pharmaceuticals less certain, that has changed the lending dynamics for a number of sub-sectors which will remain mindful of the need for further clarity.

    Looking forward to the next 12 to 18 months, the feeling was that outlook may be bumpy but can quickly change for the better. While the lack of an IPO market continues to make it difficult for biotech companies to access cash, we continue to move out of a period of economic uncertainty and so many are hopeful that equity markets will rebound in 2024. Likewise, lenders are increasingly willing to offer flexibility in the form of full PIK tranches where they have conviction, suggesting the private debt markets are continuing to find ways to support companies in dominating the debt markets.

    There is a hope that defaults will remain low through 2024 and also a recognition that, while deals are available, they may take longer to get done and diligence will be very thorough. Long term, there remains strong conviction around the growth fundamentals in our industry as well as around the potential for technology to overcome many of the structural issues that undermine the delivery of healthcare, so the return of more buoyant deal activity cannot be far off.

    Aymen Mahmoud, partner and co-head of the London Finance, Restructuring and Special Situations Group, says: “Relationships have been prioritised in 2023 and will remain the focus in 2024, with lenders looking to build productive two-way partnerships with management teams and sponsors in order to navigate balance sheet challenges.”

    He adds: “The real message from our session at the symposium was that borrowers in health and life sciences are better positioned than many in other industries when it comes to accessing the credit markets, and for the right deals there is still plenty of capital available. They should continue to expect an appropriate level of investee scrutiny from lenders through 2024, but we expect the finance markets to continue to trend to unlock throughout the year.”

    Authors

    Aymen Mahmoud

    Partner

    London – 22 Bishopsgate

    Ettore Scandale

    Partner

    Milan

    More insights